

Gary Feldman, MD
President

October 22, 2024

Madelaine Feldman, MD
VP, Advocacy & Government Affairs

Michael Saitta, MD, MBA
Treasurer

Aaron Broadwell, MD
Vice President & Secretary

Erin Arnold, MD
Director

Leyka Barbosa, MD
Director

Kostas Botsoglou, MD
Director

Michael Brooks, MD
Director

Amish Dave, MD, MPH
Director

Harry Gewanter, MD, MACR
Director

Adrienne Hollander, MD
Director

Firas Kassab, MD
Director

Robert Levin, MD
Director

Amar Majjhoo, MD
Director

Gregory Niemer, MD
Director

Joshua Stolow, MD
Director

EXECUTIVE OFFICE

Leslie Del Ponte
Executive Director

The Honorable Roy Freiman
The Honorable Gary S. Schaer
Assembly Financial Institutions and Insurance
Committee Room 11, 4th Floor
State House Annex
Trenton, NJ

Re: Support for A.4163 – Coverage for Biomarker Testing

Dear Chair Freiman, Vice Chair Schaer, and members of the Assembly Financial Institutions and Insurance Committee:

The Coalition of State Rheumatology Organizations (CSRO) is a national organization composed of over 30 state and regional professional rheumatology societies, including our member society that represents providers of rheumatology care in New Jersey. CSRO was formed by physicians to ensure excellence and access to the highest quality care for patients with rheumatologic, autoimmune, and musculoskeletal diseases.

On behalf of the CSRO, we are writing to express strong support for Assembly Bill A4163, which seeks to provide coverage for biomarker testing. As a pivotal advancement in precision medicine, biomarker tests represent an essential tool for physicians in determining the most effective treatment for individual patients based on unique biological information derived from proteins and genes.

The complexities of rheumatologic conditions often necessitate a lengthy and painful process for patients, typically characterized by a trial-and-error approach to find the right therapy. This not only prolongs patient suffering but also results in increased healthcare expenditures as patients cycle through various treatments that may not be suitable for their specific conditions. By incorporating biomarker testing into medical practice, rheumatologists can identify effective therapies more quickly, leading to timely and personalized patient care.

Biomarkers have the potential to revolutionize how we approach treatment selection, allowing for targeted therapies that can significantly improve health outcomes and quality of life for patients with rheumatologic conditions. As we move toward a healthcare landscape that emphasizes efficiency and patient-centered care, supporting A4163 is essential to ensure that these

innovative diagnostic tools are accessible to all patients who could benefit from them.

We urge the members of the Assembly Financial Institutions and Insurance Committee to support and advance A4163, recognizing the profound impact it will have on patient care and overall healthcare costs. Together, we can make strides toward a healthcare model that prioritizes precision, efficiency, and the well-being of patients.

Thank you for your consideration of this important matter.

Respectfully,

Handwritten signature of Gary Feldman in blue ink.

Gary Feldman, MD, FACR
President
Board of Directors

Handwritten signature of Madelaine A. Feldman in black ink.

Madelaine A. Feldman, MD, FACR
VP, Advocacy & Government Affairs
Board of Directors